NASDAQ:BLCM - Bellicum Pharmaceuticals, Inc.
$3.06
 $-0.15
-4.67%
4:00PM EDT
2019-04-18
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  BLCM     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 98   199. 07   233. 87  
42 stocks rank:  3. 31 K 1. 43 K 1. 06 K
# analyst opinions:  6. 00   14. 48   14. 09  

quick ratio:  5. 94   5. 29   1. 92  
current ratio:  6. 03   5. 64   2. 40  

target price low:  2. 30   84. 50   115. 74  
target price avg:  5. 20   110. 73   137. 39  
target price high:  9. 00   136. 41   157. 80  
1-yr high:  9. 93   114. 11   138. 85  
last close:  3. 06   87. 56   116. 78  
50-day avg:  3. 40   95. 43   123. 53  
200-day avg:  4. 76   94. 13   121. 20  
1-yr low:  2. 84   72. 67   98. 41  
volume:  310. 15 K 2. 43 M 4. 85 M
50-day avg volume:  376. 02 K 2. 72 M 4. 97 M
200-day avg volume:  415. 87 K 2. 90 M 4. 58 M

1-day return:  -4. 67 % -0. 40 % 0. 07 %
this week return:  -15. 24 % -5. 72 % -4. 11 %
12-wk return:  -6. 99 % 1. 78 % -0. 04 %
52-wk return:  -59. 64 % 10. 81 % 14. 09 %

enterprise value (EV):  103. 40 M 51. 19 B 117. 96 B
market cap:  135. 63 M 43. 00 B 104. 52 B
EBITDA:  -88. 77 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -1. 17   4. 34   13. 27  
enterprise/revenue (EV/R):  92. 33   68. 16   13. 68  
total revenue:  1. 12 M 10. 61 B 38. 24 B
total debt:  35. 96 M 12. 22 B 16. 66 B
debt/equity:  52. 52   46. 86   89. 46  
net income (common):  -98. 04 M 2. 20 B 4. 21 B

shares outstanding:  44. 32 M 570. 91 M 1. 24 B
shares:  41. 47 M 571. 02 M 1. 23 B
shares short:  2. 76 M 9. 93 M 16. 79 M
shares short prior month:  2. 54 M 9. 96 M 16. 58 M
short ratio:  7. 87   5. 31   3. 30  
short % of float:  10. 53 % 5. 81 % 2. 61 %
total cash/share:  2. 10   11. 13   9. 30  
total cash:  93. 00 M 6. 70 B 7. 10 B
free cash flow:  -38. 40 M 3. 58 B 4. 74 B
operating cash flow:  -74. 78 M 4. 14 B 6. 32 B

book value:  1. 57   12. 76   26. 84  
price/book:  1. 95   3. 08   -1. 74  
gross profits:  -70. 47 M 8. 03 B 34. 77 B
operating margins:  -8523. 75 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  -15. 69 % --- ---
1-yr mean volatility:  -0. 28 % 0. 03 % 0. 04 %

1-yr EPS:  -2. 44   2. 39   4. 08  
forward EPS:  -1. 98   3. 97   7. 14  
P/E:  -1. 26   13. 59   22. 83  
forward P/E:  -1. 82   -20. 05   14. 49  
PE/G:  0. 03   -1. 46   1. 68  
growth:  -42. 70 % 126. 81 % 29. 29 %
earnings high:  -0. 41   1. 02   1. 63  
earnings avg:  -0. 58   0. 76   1. 51  
earnings low:  -0. 68   0. 47   1. 39  
revenue high:  2. 70 M 2. 68 B 10. 71 B
revenue avg:  650. 00 K 2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -46. 43 % -2. 80 % 5. 29 %
return on equity:  -128. 05 % -18. 52 % 7. 38 %
revenue/share:  0. 03   13. 27   55. 24  

beta (1yr vs S&P500):  1. 28   1. 24   0. 93  
sharpe (1yr):  -1. 09   0. 29   0. 60  

held % insiders:  5. 24 % 6. 38 % 3. 38 %
held % institutions:  53. 79 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : BLCM
.        + 0 =             0 :: INITIAL WEIGHT
.   + 39.775 =        39.775 :: spline projection addition
.    x 1.432 =        56.959 :: industry recommendation factor
.    x 1.646 =        93.729 :: EV/R factor
.    x 0.995 =        93.294 :: return on assets factor
.    x 0.987 =        92.099 :: return on equity factor
.    x 2.931 =       269.902 :: current ratio factor
.    x 1.097 =       295.952 :: quick ratio factor
.    x 1.062 =       314.192 :: short ratio factor
.    x 2.019 =       634.501 :: price-to-book factor
.    x 1.371 =       869.823 :: debt-to-equity factor
.    x 2.156 =      1875.399 :: P/E weight
.    x 2.209 =       4142.68 :: PE/G factor
.    x 1.765 =      7310.606 :: beta factor
.    x 0.847 =      6195.228 :: sharpe factor
.     x 0.95 =      5886.481 :: target low factor
.    x 1.279 =      7526.609 :: target mean factor
.    x 1.139 =      8575.262 :: target high factor
.    x 1.312 =     11247.728 :: industry 2-weeks return factor
.    x 0.917 =     10316.949 :: "drift" penalty 2 days ago
.    x 0.903 =      9315.884 :: "drift" penalty 4 days ago
.     x 0.92 =      8574.152 :: "drift" penalty 5 days ago
.    x 0.957 =      8209.474 :: overall "drift" factor
.    x 0.999 =      8203.848 :: largest single-day jump factor
.    x 0.071 =       581.009 :: low price factor
.      x 1.0 =       580.915 :: factor hist industry gain for week 15
.   cubeRoot =         8.344 :: reduced to standardize
.   - 23.165 =         0.984 :: add/subtract for performance
.                      0.984 :: FINAL WEIGHT for NASDAQ:BLCM


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org